This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.
Since April 2023, over 300 shigellosis cases, many with multidrug-resistant Shigella sonnei -infections, have been reported to the European Centre for Disease Prevention and Control (ECDC).
Increased numbers of shigellosis cases, mainly caused by Shigella sonnei, among travellers returning from Cabo Verde, have been reported in the EU/EEA, the United Kingdom (UK) and the United States (US) since September 2022.
An increased reporting of shigellosis cases, mainly caused by Shigella sonnei, among travellers returning from Cabo Verde has been ongoing in the European Union/European Economic Area (EU/EEA), the United Kingdom (UK), and the United States (US) since September 2022. This outbreak evolved rapidly during November and December 2022.